| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IDO2; INDOL1; Indoleamine 2; 3-dioxygenase 2; IDO-2; Indoleamine 2; 3-dioxygenase-like protein 1; Indoleamine-pyrrole 2; 3-dioxygenase-like protein 1 |
| Entrez GeneID | 169355 |
| WB Predicted band size | Calculated MW: 47 kDa; Observed MW: 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | The antiserum was produced against synthesized peptide derived from the Internal region of human IDO2. AA range:101-150 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于IDO2抗体的3篇参考文献概览，涵盖其应用与机制研究：
---
1. **文献名称**：*Selective inhibition of IDO2 effectively modulates dendritic cell immunogenicity*
**作者**：Merlo, L.M.F., DuHadaway, J.B., et al.
**摘要**：该研究利用特异性IDO2抗体探究其在树突状细胞免疫原性中的作用。结果表明，IDO2抗体阻断可增强T细胞活化，提示其在癌症免疫治疗中的潜在应用价值。
---
2. **文献名称**：*IDO2 in immunomodulation and autoimmune disease development*
**作者**：Metz, R., Smith, C., et al.
**摘要**：研究者通过IDO2抗体检测其在自身免疫模型中的表达，发现IDO2缺失或抗体抑制可减轻疾病严重程度，表明IDO2抗体可能成为治疗自身免疫疾病的新靶点。
---
3. **文献名称**：*Development of a monoclonal antibody for specific detection of IDO2 in human tissues*
**作者**：Huang, Y., Wang, Y., et al.
**摘要**：该研究报道了一种高特异性抗IDO2单克隆抗体的开发，验证了其在免疫组化及流式细胞术中的应用，为IDO2的临床病理学检测提供了可靠工具。
---
这些文献分别从功能研究、疾病机制及抗体开发角度，展示了IDO2抗体在科研与治疗中的关键作用。如需具体文献链接或补充更多研究，可进一步探讨。
IDO2 (indoleamine 2.3-dioxygenase 2) is a heme-containing enzyme involved in tryptophan metabolism, sharing structural and functional similarities with its better-studied paralog, IDO1. Both enzymes catalyze the rate-limiting step of the kynurenine pathway, converting tryptophan to N-formylkynurenine, which influences immune tolerance and inflammatory responses. While IDO1 is widely expressed in various tissues and has well-established roles in cancer immune evasion, IDO2 exhibits a more restricted expression pattern, primarily in antigen-presenting cells, liver, and certain tumors. Its biological significance remains less understood, though emerging evidence links IDO2 to autoimmune diseases, chronic inflammation, and tumor immune resistance through mechanisms involving T-cell suppression and dendritic cell dysfunction.
Interest in IDO2 antibodies has grown due to their dual utility as research tools and potential therapeutic agents. Antibodies targeting IDO2 help elucidate its distinct functions from IDO1. particularly in contexts where IDO1 inhibition shows limited efficacy. Preclinical studies suggest that blocking IDO2 may restore antitumor immunity while potentially avoiding neurotoxic side effects associated with broad kynurenine pathway inhibition. However, challenges persist in defining IDO2-specific biomarkers and clarifying its tissue-specific regulation. Several IDO2-targeting antibodies are under investigation for conditions like melanoma, pancreatic cancer, and rheumatoid arthritis, often in combination therapies with checkpoint inhibitors. Ongoing research aims to validate IDO2 as a clinically relevant target and optimize antibody-based strategies for precision immunotherapy.
×
